Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harten

Showing results (41-50 of 863) with videos related to

Pageof 87
Sort By:
Current Genetics|November 5, 2013
Physical mapping of 4S RNA genes on chloroplast DNA of Spirodela oligorhizaG S Groot, N van Harten-Loosbroek
Nederlands Tijdschrift Voor Geneeskunde|September 30, 1998
[For how long should antipsychotic medication be continued after the first psychotic episode in schizophrenics?]P N van Harten, H W Hoek
Nederlands Tijdschrift Voor Geneeskunde|November 26, 1994
[acute dystonias in combined abuse of cocaine and neuroleptics]E H Horwitz, P N van Harten
Handbook of Clinical Neurology|November 16, 2019
The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystoniaPascal Sienaert, Peter van Harten, Didi Rhebergen
Nederlands Tijdschrift Voor Geneeskunde|April 18, 1992
[Psychogenic aphonia; an effective and rapidly treatable conversion]P N van Harten, H K Schutte
Cancers|July 2, 2021
Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic ApplicationsAnne M van Harten, Ruud H Brakenhoff
Journal of Health Organization and Management|October 17, 2017
Dealing with a changing work environment: hospital job type contingenciesJasmijn van Harten, Eva Knies, Peter Leisink
Ecancermedicalscience|December 21, 2016
Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncologyW H van Harten, V P Retèl
Ecancermedicalscience|December 1, 2016
Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementationW H van Harten, V P Retèl
Journal of Cancer Policy|May 13, 2022
Securing sustainable price levels of innovative anticancer drugs: How to move forward?N Franzen, V Retèl, W van Harten
Pageof 87

Showing results (41-50 of 863) with videos related to

Sort By:
Pageof 87
Current Genetics|November 5, 2013
Physical mapping of 4S RNA genes on chloroplast DNA of Spirodela oligorhizaG S Groot, N van Harten-Loosbroek
Nederlands Tijdschrift Voor Geneeskunde|September 30, 1998
[For how long should antipsychotic medication be continued after the first psychotic episode in schizophrenics?]P N van Harten, H W Hoek
Nederlands Tijdschrift Voor Geneeskunde|November 26, 1994
[acute dystonias in combined abuse of cocaine and neuroleptics]E H Horwitz, P N van Harten
Handbook of Clinical Neurology|November 16, 2019
The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystoniaPascal Sienaert, Peter van Harten, Didi Rhebergen
Nederlands Tijdschrift Voor Geneeskunde|April 18, 1992
[Psychogenic aphonia; an effective and rapidly treatable conversion]P N van Harten, H K Schutte
Cancers|July 2, 2021
Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic ApplicationsAnne M van Harten, Ruud H Brakenhoff
Journal of Health Organization and Management|October 17, 2017
Dealing with a changing work environment: hospital job type contingenciesJasmijn van Harten, Eva Knies, Peter Leisink
Ecancermedicalscience|December 21, 2016
Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncologyW H van Harten, V P Retèl
Ecancermedicalscience|December 1, 2016
Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementationW H van Harten, V P Retèl
Journal of Cancer Policy|May 13, 2022
Securing sustainable price levels of innovative anticancer drugs: How to move forward?N Franzen, V Retèl, W van Harten
Pageof 87